[Anticoagulation in patients with chronic renal failure].
Anticoagulation may be difficult to implement in patients suffering from chronic renal failure on account of platelet disorders and impaired clearance of some anticoagulant drugs. Although no adjustment of heparin and coumarin dosage is necessary, more frequent testing of coagulation pathways may be required when these drugs are used in patients with renal failure. Long-term use of LMWH should be implemented cautiously with regular testing of anti-factor Xa activity and a half-dose may be advocated in patients with a creatinine clearance < 30 ml/mn. Danaparoid and thrombin inhibitors should be used mainly in patients suffering from renal failure and heparin-induced thrombocytopenia with regular monitoring of coagulation tests.
Niksic
L
L
Service de néphrologie, HUG, 1211 Genève 14. Laurent.Niksic@hcuge.ch
Saudan
P
P
Boehlen
F
F
D000925:Anticoagulants / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D006435:Renal Dialysis; D013917:Thrombin / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D006493:Heparin; D013917:Thrombin